Israeli startup CytoReason today announced a partnership with Swiss multinational, Ferring Pharmaceuticals, to establish new treatments for inflammatory bowel disease (IBD).
Read more here.
![[MasterClass in The New York Times] It’s the Year 2120. MasterClass Is the Only School Left](https://blog.ourcrowd.com/wp-content/themes/Extra/images/post-format-thumb-text.svg)
[MasterClass in The New York Times] It’s the Year 2120. MasterClass Is the Only School Left
May 25, 2020
[BlueNalu in SeafoodSource] BlueNalu secures investment from Sumitomo Corporation of Americas
June 1, 2020
